...granted Orphan Drug designation for Elorac's naloxone lotion to treat cutaneous T cell lymphoma (CTCL). Elorac...
...designation in the U.S. to treat pruritus accompanying mycosis fungoides, a common type of CTCL. Elorac Inc....

...FDA granted Orphan Drug designation for Elorac's naloxone lotion for the topical treatment of pruritus accompanying...
...The opiate antagonist is slated to begin Phase III testing for the indication in 4Q11. Elorac Inc....

...in the U.S. The cost of the rapid release microcrystalline encapsulated anthralin cream is undisclosed. Elorac Inc....